[1] 刘晋, 于皆平, 王晓玲, 周晓东, 于红刚. 环氧合酶-2和血管内皮生长因子-C与胃癌淋巴管转移 [J]. 中华内科杂志 2004.doi:10.3760/j.issn:0578-1426.2004.11.011
[2] 赵丽红, 武云霞, ZHAO Lihong, WU Yunxia. Survivin和Cyclin D1在涎腺多形性腺瘤中的表达及意义 [J]. 中国现代医生 2012.doi:10.3969/j.issn.1673-9701.2012.18.016
[3] 史建洁, 董福生, 任贵云. 涎腺腺样囊性癌中Survivin与nm23表达的研究 [J]. 山东医药 2011.doi:10.3969/j.issn.1002-266X.2011.52.036
[4] 王旭, 王洁, 董福生, 董玉英, 侯亚丽. COX-2及survivin在涎腺多形性腺瘤中表达的定量研究 [J]. 山东医药 2005.doi:10.3969/j.issn.1002-266X.2005.12.001
[5] 李海峰, 刘铁军, 刘海波, 刘爽, LI Hai-feng, LIU Tie-jun, LIU Hai-bo, LIU Shuang. COX-2及Survivin在涎腺腺样囊性癌中的表达 [J]. 河北医科大学学报 2008.doi:10.3969/j.issn.1007-3205.2008.05.017
[6] 朱建华, 林兆全, 王志宏, 凌彬. Cox-2和Ki-67在涎腺导管癌中的表达及临床意义 [J]. 武警医学 2010.doi:10.3969/j.issn.1004-3594.2010.04.015
[7] 朱建华, 仲琳, ZHU Jianhua, ZHONG Lin. 涎腺导管癌组织中Cox-2和EZH2的表达及意义 [J]. 包头医学院学报 2011.doi:10.3969/j.issn.1006-740X.2011.03.005
[8] 李晓光, 袁丽丽, 肖长杰, 王延秀, LI Xiao-guang, YUAN Li-li, XIAO Chang-jie, WANG Yan-xiu. 涎腺腺样囊性癌COX-2表达与肿瘤血管生成的研究 [J]. 临床口腔医学杂志 2011.doi:10.3969/j.issn.1003-1634.2011.02.001
[9] 李善昌, 郭宏, LI Shan-chang, GUO Hong. COX-2在涎腺恶性肿瘤中的表达及其意义 [J]. 黑龙江医药科学 2009.doi:10.3969/j.issn.1008-0104.2009.02.016
[10] 符良斌, 廖天安, 刘正, 王鸿, 王友元, 黄志权. Survivin、Ki-67核抗原在涎腺基底细胞腺瘤、癌中的意义 [J]. 中国实验诊断学 2010.doi:10.3969/j.issn.1007-4287.2010.12.024
[11] 刘敏. Survivin、COX-2在涎腺腺样囊性癌中的表达研究 [D]. 遵义医学院 2004.
[12] 马湘一, 何福仙, 邬素芳, 卢运萍, 马丁. 卵巢上皮癌组织中survivin的表达及其与Fas、FasL表达的关系 [J]. 癌症 2004.doi:10.3321/j.issn:1000-467X.2004.02.013
[13] 崔玮. Survivin反义寡核苷酸治疗人涎腺腺样囊性癌的实验研究 [D]. 河北医科大学 2008.
[14] 王滔明. Survivin、COX-2和VEGF在早、中期胃癌组织中的表达及其与预后的关系 [D]. 安徽医科大学 2005.
[15] 史建洁, 李大海, 王阳阳. 涎腺腺样囊性癌组织中survivin、COX-2的表达变化及意义 [J]. 山东医药 2011.doi:10.3969/j.issn.1002-266X.2011.50.073
[16] 李文超. 成釉细胞瘤中Survivin和COX-2的表达及意义 [D]. 石河子大学 2011.
[17] 马大权. 涎腺疾病 [M]. 北京:人民卫生出版社 2002.
[18] Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neoptolemos JP. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. [J]. Gene therapy 2001, 3(3).
[19] Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. [J]. Clinical cancer research: an official journal of the American Association for Cancer Research 2008, 16(16).
[20] O'Connor, DS, Schechner, JS, Adida, C, Mesri, M, Rothermel, AL, Li, F, Nath, AK, Pober, JS, Altieri, DC. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. [J]. American Journal of Pathology 2000, 2(2).
[21] LIU X, KIRSCHENBUAM A, YAO S. Up-regulation of Vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclcoxygenase-2 in a metastatic human prostate cancer cellines [J]. Clinical & Experimental Metastasis 1999, 17(08).
[22] Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. [J]. The Journal of Clinical Investigation: The Official Journal of the American Society for Clinical Investigation 2001, 7(7).
[23] DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. [J]. Cancer research 1996, 4(4).
[24] AMBROSINI G, ADIDA C, ALTIERI D C. A novel ant-apoptosis gene, survivin, expressed in cancer and Iymphoma [J]. Nature Medicine 1997, 3(08).
[25] Kumamoto H, Ooya K. [J]. Virchows Archiv: an international journal of pathology 2004.
[26] SHIGEMASS K, TIAN X, Gu L. Cyclooxygenase-2 and its relationship to P53 accumulation in ovarian adenocarcinomas [J]. International Journal of Oncology 2003, 22(01).
[27] Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. [J]. Clinical colorectal cancer 2011, 3(3).
[28] Newcomb EW. [J]. Anti-cancer drugs 2004.
[29] TSURUMA T, HALA F, TORIGOE T. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine thera-PY for patients with advanced or recurrent colorectal cancer [J]. Journal of Translational Medicine 2004, 2(01).
[30] KINUGASA Y, HATORI M, ITO H. Inhibition of cyclooxy genase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of MMP-2 and CD44 [J]. Clinical & Experimental Metastasis 2004, 21.
[31] RODRIGUEZ D A, TAPIA J C, FEMANDERZ. Caveolin-l-mediated suppression of cyclooxygenase-2 via a β-catenin-Tef/Lef-dependent transcriptional mechanlism reduced prostaglandin E2 production and surviving expression [J]. Molecular Biology of the Cell 2009, 20(08). |
